Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Anteris Technologies Global Corp. (AVR)
A forensic read on Anteris Technologies Global Corp. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-81.6
Altman Z-score
Clean
Earnings quality
2
Forensic signals
-64.7%
ROE
$943M
Market cap
Anteris Technologies Global Corp. earns a F (Poor — capital at risk) forensic quality grade, and its Altman Z-score is -81.6, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.
What the filings flag
+82.3%/yrShare-count dilution.Diluted share count changed +82% over the last 1 years to FY2025 (+82.3%/yr). The count is GROWING — existing holders are being diluted. That's ~82.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2024 has been diluted ~82%.
407% of revStock-based comp load.Stock-based compensation ran 407% of revenue in FY2025 — about $0.21 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-4921.3%
Free Cash Flow$-79.8M
Latest Revenue$1.9M
Revenue Growth YoY-29.2%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Anteris Technologies Global Corp.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about AVR's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown